In this article
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration had threatened legal action against Hims & Hers, which announced over the weekend it would not sell the pill.
“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” Hims & Hers posted on social media on Saturday.
“As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.”
